Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Pegylated interferon plus ribavirin showed no clear difference in end‐of‐treatment response compared with pegylated interferon alone (low certainty).
Pegylated interferon plus ribavirin may leads to higher sustained virological response compared with pegylated interferon alone (low certainty).
Pegylated interferon plus ribavirin showed no clear difference in treatment discontinuation compared with pegylated interferon alone (low certainty).
Pegylated interferon plus ribavirin may leads to higher adverse events compared with pegylated interferon alone (low certainty).
The review found no eligible studies for this question.
Standard interferon showed no clear difference in sustained virological response 6 months after stopping treatment compared with placebo or control (moderate certainty).
The review found no eligible studies for this question.
Direct antivirals (grazoprevir and elbasvir) may leads to higher end‐of‐treatment response compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether pegylated interferon + ribavirin (24 weeks) + initial telepravir (12… changes sustained virological response compared with pegylated interferon (48 weeks) + initial telepravir (12 weeks) +… (very low certainty).
It is very uncertain whether pegylated interferon + ribavirin (24 weeks) + initial telepravir (12… changes end‐of‐treatment response compared with pegylated interferon (48 weeks) + initial telepravir (12 weeks) +… (very low certainty).
The review found no eligible studies for this question.
Standard interferon showed no clear difference in treatment discontinuation compared with placebo or control (moderate certainty).
The review found no eligible studies for this question.
Standard interferon showed no clear difference in adverse events compared with placebo or control (moderate certainty).
Pegylated interferon alpha‐2a showed no clear difference in death compared with standard interferon (low certainty).